In the past decade, advances in endocrine therapy and anti-human epidermal growth factor receptor 2 (HER2) therapy have remarkably improved the survival of estrogen receptor (ER) positive and HER2 positive breast cancer patients. Here, ESR1 is linked to breast cancer.